Adeno-Associated Viruses (AAVs) have been a prevalent platform for gene delivery due to their simple structure and genome, lack of pathogenicity, and low immunogenicity. However, like other viral vectors, AAV's transduction pathway is dictated by the natural tropism of the capsid. As such, a significant portion of AAV research has covered mutating the naturally occurring AAV capsids to create unique capsid sequences by replacing or adding sequence elements to alter the capsid's tropism to target specific organs or sites of disease, such as cancer.
This webinar will focus on the development and use of protease-activatable AAV vectors, known as provectors, to target sites of enzyme over-expression such as matrix metalloproteases (MMPs). We will discuss how, through the use of precisely created mutant libraries, we can optimize the ON state of provectors to enhance transduction efficiency and improve targeted delivery.
Learning outcome from this webinar:
- Development and use of protease-activatable AAV vectors (provectors) to control viral targeting
- Engineering provector scar to improve transduction efficiency
- How precisely designed mutant libraries can be used to improve activatable behavior of provectors
Susan Butler is a Ph.D. Candidate of Bioengineering at Rice University awarded an NIH T32 MD Anderson/Rice Cancer Nanotechnology Predoctoral Fellowship. She completed her undergraduate education in Biomedical Engineering at the University of Rochester in 2016. Currently, she engineers activatable adeno-associated viral vectors, known as Provectors, to target sites of protease overexpression in pancreatic ductal adenocarcinoma. In order to characterize and improve the rationally designed system of activatable vectors, she has turned to library exploration of the activatable system.